AbbVie

These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Biogen
aducanumab
JNJ
apalutamide
Eli Lilly
abemaciclib
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
Flag link:
5 Big Pharma Stocks With the Best Drug Pipelines
5 Big Pharma Stocks With the Best Drug Pipelines
Motley Fool
Big Pharma
Roche
AstraZeneca
AbbVie
Gilead Sciences
JNJ
Flag link:
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Flag link:
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
Motley Fool
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
AbbVie
JNJ
Imbruvica
Pfizer
Ibrance
cancer
Flag link:
Key Humira patent gets struck down for the second time in as many months
Key Humira patent gets struck down for the second time in as many months
Fierce Pharma
Humira
patents
AbbVie
Boehringer Ingelheim
Coherus Biosciences
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
Motley Fool
AbbVie
biosimilars
Humira
Clovis Oncology
Rubraca
Novartis
Regeneron
Eylea
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Motley Fool
AbbVie
Humira
Upadacitinib
JAK inhibitors
autoimmune disease
Flag link:
AbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher
AbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher
Motley Fool
AbbVie
Humira
Flag link:
First PhIII trial of AbbVie’s upadacitinib a success
First PhIII trial of AbbVie’s upadacitinib a success
Pharma Times
AbbVie
Upadacitinib
clinical trials
rheumatoid arthritis
Flag link:
Abbvie Vaults First Pivotal Hurdle With Oral RA Candidate
Abbvie Vaults First Pivotal Hurdle With Oral RA Candidate
Seeking Alpha
AbbVie
rheumatoid arthritis
Upadacitinib
Flag link:
AbbVie, Novo Nordisk and Takeda Have the Best Reputations Among Pharma Companies According to Reputation Institute Global Pharma Reptrak® Study
AbbVie, Novo Nordisk and Takeda Have the Best Reputations Among Pharma Companies According to Reputation Institute Global Pharma Reptrak® Study
PR Web
reputation
AbbVie
Novo Nordisk
Takeda
Flag link:
Top Presentations to Look for at ASCO
Top Presentations to Look for at ASCO
Yahoo/24-7 Wall St
ASCO 2017
Merck
AbbVie
Eli Lilly
Bluebird Bio
Epizyme
Juno Therapeutics
Kite
Merus
Flag link:
AbbVie preps an FDA pitch of promising PhIII data for blockbuster hopeful elagolix
AbbVie preps an FDA pitch of promising PhIII data for blockbuster hopeful elagolix
Endpoints
AbbVie
Elagolix
clinical trials
endometriosis
Flag link:
Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Fierce Pharma
Humira
patents
AbbVie
biosimilars
Flag link:
AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
BioPharma Dive
AbbVie
JAK inhibitors
Crohn's Disease
Upadacitinib
Flag link:
Gilead Vs. AbbVie: A DGI Thunderdome Match
Gilead Vs. AbbVie: A DGI Thunderdome Match
Seeking Alpha
Gilead Sciences
AbbVie
Flag link:
AbbVie Is Focused on Label Expansion of Imbruvica in 2017
AbbVie Is Focused on Label Expansion of Imbruvica in 2017
Market Realist
AbbVie
Imbruvica
non-Hodgkin's lymphoma
mantle cell lymphoma
graft vs host disease
Flag link: